GSK Secures Japan Regulatory Review For Bepirovirsen In Chronic Hepatitis B, Targeting Nearly 1 Million Patients With First Global Regulatory Filing

GlaxoSmithKline plc Sponsored ADR
Ishares Msci Japan Index Fund

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

Ishares Msci Japan Index Fund

EWJ

0.00
  • Submission supported by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal phase III B-Well trials
  • Nearly 1 million people in Japan live with chronic hepatitis B1, a leading cause of liver cancer2  
  • First regulatory filing globally, with SENKU designation enabling expedited review3  

 

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.